» Articles » PMID: 30506717

Trehalose Administration Attenuates Atherosclerosis in Rabbits Fed a High-fat Diet

Overview
Journal J Cell Biochem
Date 2018 Dec 4
PMID 30506717
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Disruption of macrophage autophagy is a major contributor to macrophage dysfunction and subsequent inflammation leading to atherosclerosis. Trehalose is a natural disaccharide that is able to induce macrophage autophagy-lysosomal biogenesis and reduce inflammation. Here, we studied the efficacy of intravenous trehalose administration in reducing atherosclerotic plaque burden in high-cholesterol-fed rabbits. Adult male New Zealand white Rabbits were fed with a high-fat diet containing 1% cholesterol for 8 weeks followed by a cholesterol-free diet for the next 4 weeks. In the latter 4-week phase of the cholesterol-free diet, one group received intravenous trehalose solution at a dose of 350 mg/kg, three times per week. In the control group, an equivalent volume of PBS (3 mL) was administered with the same protocol. At the end of the 12th week of the study, all rabbits were anesthetized and aortic arch sections were collected followed by hematoxylin and eosin staining and assessment of plaque grading. Fasting serum lipids were also measured using routine enzymatic methods. At the end of the 12th week, there were no significant differences in the body weight and blood lipids between the control- and trehalose-treated groups. Intravenous trehalose administration significantly attenuated atherosclerotic plaque development as revealed by reduced plaque grading ( P = 0.048) and intima/media thickness ratio ( P = 0.017). Intimal thickening was also found to be reduced in the trehalose versus control group, though this reduction did not reach statistical significance. The present study provided evidence as to the efficacy of short-term intravenous trehalose administration in regressing atherosclerotic plaque in high-fat-fed rabbits.

Citing Articles

Hepatocyte MMP14 mediates liver and inter-organ inflammatory responses to diet-induced liver injury.

Kelly S, Higgins C, Sun J, Adams J, Zhang Y, Ballentine S PNAS Nexus. 2024; 3(9):pgae357.

PMID: 39282008 PMC: 11393575. DOI: 10.1093/pnasnexus/pgae357.


Effect of trehalose on mortality and disease severity in ICU-admitted patients: Protocol for a triple-blind, randomized, placebo-controlled clinical trial.

Sahranavard M, Hosseinjani H, Emadzadeh M, Jamialahmadi T, Sahebkar A Contemp Clin Trials Commun. 2024; 40:101324.

PMID: 39021672 PMC: 11252791. DOI: 10.1016/j.conctc.2024.101324.


Nanogels with covalently bound and releasable trehalose for autophagy stimulation in atherosclerosis.

Zhong Y, Maruf A, Qu K, Milewska M, Wandzik I, Mou N J Nanobiotechnology. 2023; 21(1):472.

PMID: 38066538 PMC: 10704736. DOI: 10.1186/s12951-023-02248-9.


The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial.

Hashemian S, Shojaei M, Radbakhsh S, Ashari S, Riahi M, Shateri Amiri Z Arch Med Sci. 2023; 19(6):1693-1700.

PMID: 38058700 PMC: 10696978. DOI: 10.5114/aoms/159048.


The effect of intravenous trehalose administration in a patient with multiple sulfatase deficiency.

Radbakhsh S, Mobini M, Gumpricht E, Banach M, Jamialahmadi T, Sahebkar A Arch Med Sci. 2023; 19(5):1564-1568.

PMID: 37732042 PMC: 10507772. DOI: 10.5114/aoms/159711.